Novel immunotherapeutics against LGR5 to target multiple cancer types.
ADC
BiTE
CAR
Cancer Immunotherapeutics
LGR5
Journal
EMBO molecular medicine
ISSN: 1757-4684
Titre abrégé: EMBO Mol Med
Pays: Germany
ID NLM: 101487380
Informations de publication
Date de publication:
21 Aug 2024
21 Aug 2024
Historique:
received:
16
02
2024
accepted:
01
08
2024
revised:
30
07
2024
medline:
22
8
2024
pubmed:
22
8
2024
entrez:
21
8
2024
Statut:
aheadofprint
Résumé
We have developed and validated a highly specific, versatile antibody to the extracellular domain of human LGR5 (α-LGR5). α-LGR5 detects LGR5 overexpression in >90% of colorectal cancer (CRC), hepatocellular carcinoma (HCC) and pre-B-ALL tumour cells and was used to generate an Antibody-Drug Conjugate (α-LGR5-ADC), Bispecific T-cell Engager (α-LGR5-BiTE) and Chimeric Antigen Receptor (α-LGR5-CAR). α-LGR5-ADC was the most effective modality for targeting LGR5
Identifiants
pubmed: 39169164
doi: 10.1038/s44321-024-00121-2
pii: 10.1038/s44321-024-00121-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Cancer Research UK (CRUK)
ID : A22257
Organisme : Cancer Research UK (CRUK)
ID : C67279/A27957
Organisme : Cancer Research UK (CRUK)
ID : RCCCSF-May23/100001
Organisme : Cancer Research UK (CRUK)
ID : C63389/A30462
Organisme : Cancer Research UK (CRUK)
ID : C52489/A19924
Organisme : Cancer Research UK (CRUK)
ID : C18873/A26813
Organisme : Wellcome Trust (WT)
ID : 107609/Z/15/Z
Organisme : Wellcome Trust (WT)
ID : 227432/Z/23/Z
Organisme : Wellcome Trust (WT)
ID : 203151/Z/16/Z
Organisme : Wellcome Trust (WT)
ID : 222062/Z/20/Z
Organisme : UKRI | Medical Research Council (MRC)
ID : RG94521
Organisme : Pathological Society of Great Britain and Ireland
ID : 3903171
Informations de copyright
© 2024. The Author(s).
Références
Adams GP, Weiner LM (2005) Monoclonal antibody therapy of cancer. Nat Biotechnol 23:1147–1157
pubmed: 16151408
doi: 10.1038/nbt1137
Bargh JD, Walsh SJ, Isidro-Llobet A, Omarjee S, Carroll JS, Spring DR (2020) Sulfatase-cleavable linkers for antibody-drug conjugates. Chem Sci 11:2375–2380
pubmed: 34084399
pmcid: 8157321
doi: 10.1039/C9SC06410A
Barker N, Huch M, Kujala P, van de Wetering M, Snippert HJ, van Es JH, Sato T, Stange DE, Begthel H, van den Born M et al (2010) Lgr5+ve stem cells drive self-renewal in the stomach and build long-lived gastric units in vitro. Cell Stem Cell 6:25–36
pubmed: 20085740
doi: 10.1016/j.stem.2009.11.013
Barker N, Rookmaaker MB, Kujala P, Ng A, Leushacke M, Snippert H, van de Wetering M, Tan S, Van Es JH, Huch M et al (2012) Lgr5+ve stem/progenitor cells contribute to nephron formation during kidney development. Cell Rep 2:540–552
pubmed: 22999937
doi: 10.1016/j.celrep.2012.08.018
Berraondo P, Ochoa MC, Olivera I, Melero I (2019) Immune desertic landscapes in hepatocellular carcinoma shaped by β-catenin activation. Cancer Discov 9:1003–1005
pubmed: 31371324
doi: 10.1158/2159-8290.CD-19-0696
Carmon KS, Gong X, Yi J, Wu L, Thomas A, Moore CM, Masuho I, Timson DJ, Martemyanov KA, Liu QJ (2017) LGR5 receptor promotes cell-cell adhesion in stem cells and colon cancer cells via the IQGAP1-Rac1 pathway. J Biol Chem 292:14989–15001
pubmed: 28739799
pmcid: 5592675
doi: 10.1074/jbc.M117.786798
Chen H, Eling N, Martinez‐Jimenez CP, O’Brien LM, Carbonaro V, Marioni JC, Odom DT, Roche M (2019) IL ‐7‐dependent compositional changes within the γδ T cell pool in lymph nodes during ageing lead to an unbalanced anti‐tumour response. EMBO Rep 20:1–17
doi: 10.15252/embr.201847379
Chen P, Chen X, Lin Z, Dev G, Chen P, Chen X, Lin Z, Fang D, He X (2013) The structural basis of R-spondin recognition by LGR5 and RNF43. Genes Dev 27:1345–1350
pubmed: 23756651
pmcid: 3701190
doi: 10.1101/gad.219915.113
Cosgun KN, Robinson M, Deb G, Yang X, Xiao G, Sadras T, Lee J, Chan L, Kume K, Mangolini M et al (2020) Lgr5-mediated restraint of β-catenin is essential for B-lymphopoiesis and leukemia-initiation. Preprint – BioRxiv
Cosgun KNN, Hecht A, Yang X, Mangolini M, Aghajanirefah A, Chen Z, Xiao G, Klemm L, Hong C, Geng H et al (2017) Lgr5 functions as negative regulator of Wnt signaling in B cells and is critical for self-renewal of normal and transformed B cells. Blood 130:3989
De La Roche M, Asano Y, Griffiths GM (2016) Origins of the cytolytic synapse. Nat Rev Immunol 16:421–432
pubmed: 27265595
doi: 10.1038/nri.2016.54
De La Roche M, Ibrahim AEK, Mieszczanek J, Bienz MLEF1 (2014) and B9L shield b-catenin from inactivation by axin desensitizing colorectal cancer cells to tankyrase inhibitors. Cancer Res 74:1495–1505
pubmed: 24419084
pmcid: 3947273
doi: 10.1158/0008-5472.CAN-13-2682
De Lau W, Barker N, Low TY, Koo BK, Li VSW, Teunissen H, Kujala P, Haegebarth A, Peters PJ, Van De Wetering M et al (2011) Lgr5 homologues associate with Wnt receptors and mediate R-spondin signalling. Nature 476:293–297
pubmed: 21727895
doi: 10.1038/nature10337
Drago JZ, Modi S, Chandarlapaty S (2021) Unlocking the potential of antibody–drug conjugates for cancer therapy. Nat Rev Clin Oncol 18:327–344
pubmed: 33558752
pmcid: 8287784
doi: 10.1038/s41571-021-00470-8
Fritz JM, Lenardo MJ (2019) Development of immune checkpoint therapy for cancer. J Exp Med 216:1244–1254
pubmed: 31068379
pmcid: 6547853
doi: 10.1084/jem.20182395
Fumagalli A, Oost KC, Kester L, Morgner J, Bornes L, Bruens L, Spaargaren L, Azkanaz M, Schelfhorst T, Beerling E et al (2020) Plasticity of Lgr5-negative cancer cells drives metastasis in colorectal cancer. Cell Stem Cell 26:569–578.e7
pubmed: 32169167
pmcid: 7118369
doi: 10.1016/j.stem.2020.02.008
Galarreta MR, De Bresnahan E, Molina-sánchez P, Lindblad KE, Maier B, Sia D, Puigvehi M, Miguela V, Casanova-acebes M, Dhainaut M et al (2019) β-catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma. Cancer Discov 9:1124–1141
doi: 10.1158/2159-8290.CD-19-0074
Gong X, Azhdarinia A, Ghosh SC, Xiong W, An Z, Liu Q, Carmon KS (2016) LGR5-Targeted antibody-drug conjugate eradicates gastrointestinal tumors and prevents recurrence. Mol Cancer Ther 15:1580–1590
pubmed: 27207778
doi: 10.1158/1535-7163.MCT-16-0114
Haegebarth A, Clevers H (2009) Wnt signaling Lgr5 and stem cells in the intestine and skin. Am J Pathol 174:715–721
pubmed: 19197002
pmcid: 2665733
doi: 10.2353/ajpath.2009.080758
Hagerling C, Owyong M, Sitarama V, Wang CY, Wang CY, Lin C, Van Den Bijgaart RJE, Van Den Bijgaart RJE, Koopman CD, Koopman CD et al (2020) LGR5 in breast cancer and ductal carcinoma in situ: A diagnostic and prognostic biomarker and a therapeutic target. BMC Cancer 20:1–14
doi: 10.1186/s12885-020-06986-z
Herpers B, Eppink B, James MI, Cortina C, Cañellas-Socias A, Boj SF, Hernando-Momblona X, Glodzik D, Roovers RC, van de Wetering M et al (2020) Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors. Nat Cancer 3:418–436
doi: 10.1038/s43018-022-00359-0
Huch M, Dorrell C, Boj SF, Van Es JH, Li VSW, Van De Wetering M, Sato T, Hamer K, Sasaki N, Finegold MJ et al (2013) In vitro expansion of single Lgr5 + liver stem cells induced by Wnt-driven regeneration. Nature 494:247–250
pubmed: 23354049
pmcid: 3634804
doi: 10.1038/nature11826
James JR (2018) Tuning ITAM multiplicity on T cell receptors can control potency and selectivity to ligand density. Sci Signal 11:eaan1088
pubmed: 29789296
pmcid: 6517276
doi: 10.1126/scisignal.aan1088
Junttila MR, Mao W, Wang X, Wang BE, Pham T, Flygare J, Yu SF, Yee S, Goldenberg D, Fields C et al (2015) Targeting LGR5+ cells with an antibody-drug conjugate for the treatment of colon cancer. Sci Transl Med 7:1–12
doi: 10.1126/scitranslmed.aac7433
Kobayashi S, Yamada-Okabe H, Suzuki M, Natori O, Kato A, Matsubara K, Chen YJ, Yamazaki M, Funahashi S, Yoshida K et al (2012) LGR5-positive colon cancer stem cells interconvert with drug-resistant LGR5-negative cells and are capable of tumor reconstitution. Stem Cells 30:2631–2644
pubmed: 23081779
doi: 10.1002/stem.1257
Koo BK, Clevers H (2014) Stem cells marked by the r-spondin receptor LGR5. Gastroenterology 147:289–302
pubmed: 24859206
doi: 10.1053/j.gastro.2014.05.007
Korinek V, Barker N, Morin PJ, Van Wichen D, De Weger R, Kinzler KW, Vogelstein B, Clevers H (1997) Constitutive transcriptional activation by a β-catenin-Tcf complex in APC(-/-) colon carcinoma. Science 275:1784–1787
pubmed: 9065401
doi: 10.1126/science.275.5307.1784
Law CW, Chen Y, Shi W, Smyth GK (2014) Voom: precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol 15:1–17
Leung C, Tan SH, Barker N (2018) Recent advances in Lgr5+ stem cell research. Trends Cell Biol 28:380–391
pubmed: 29477614
doi: 10.1016/j.tcb.2018.01.010
Löffler A, Kufer P, Lutterbüse R, Zettl F, Daniel PT, Schwenkenbecher JM, Riethmüller G, Dörken B, Bargou RC (2000) A recombinant bispecific single-chain antibody CD19 x CD3 induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 95:2098–2103
pubmed: 10706880
doi: 10.1182/blood.V95.6.2098
McClanahan T, Koseoglu S, Smith K, Grein J, Gustafson E, Black S, Kirschmeier P, Samatar AA (2006) Identification of overexpression of orphan G Protein-Coupled Receptor GPR49 in human colon and ovarian primary tumors. Cancer Biol Ther 5:419–426
pubmed: 16575208
doi: 10.4161/cbt.5.4.2521
Mitwasi N, Feldmann A, Arndt C, Koristka S, Berndt N, Jureczek J, Loureiro LR, Bergmann R, Máthé D, Hegedüs N et al (2020) “UniCAR”-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells. Sci Rep 10:1–16
doi: 10.1038/s41598-020-59082-4
Morgan RG, Mortensson E, Williams AC (2018) Targeting LGR5 in colorectal cancer: therapeutic gold or too plastic? Br J Cancer 118:1410–1418
pubmed: 29844449
pmcid: 5988707
doi: 10.1038/s41416-018-0118-6
Nakata S, Campos B, Bageritz J, Lorenzo Bermejo J, Becker N, Engel F, Acker T, Momma S, Herold-Mende C, Lichter P et al (2013) LGR5 is a marker of poor prognosis in glioblastoma and is required for survival of brain cancer stem-like cells. Brain Pathol 23:60–72
pubmed: 22805276
doi: 10.1111/j.1750-3639.2012.00618.x
Nguyen HG, Blank A, Dawson HE, Lugli A, Zlobec I (2020) Classification of colorectal tissue images from high throughput tissue microarrays by ensemble deep learning methods. Sci Rep 11:1–11
Nusse R, Clevers H (2017) Wnt/β-catenin signaling disease and emerging therapeutic modalities. Cell 169:985–999
pubmed: 28575679
doi: 10.1016/j.cell.2017.05.016
Peng WC, DeLau W, Forneris F, Granneman JCM, Huch M, Clevers H, Gros P (2013) Structure of stem cell growth factor R-spondin 1 in complex with the ectodomain of its receptor LGR5. Cell Rep 3:1885–1892
pubmed: 23809763
doi: 10.1016/j.celrep.2013.06.009
Rossmann M, Greive SJ, Moschetti T, Dinan M, Hyvönen M (2017) Development of a multipurpose scaffold for the display of peptide loops. Protein Eng Des Sel 30:419–430
pubmed: 28444399
pmcid: 5897841
doi: 10.1093/protein/gzx017
Sato T, Stange DE, Ferrante M, Vries RGJ, Van Es JH, Van Den Brink S, Van Houdt WJ, Pronk A, Van Gorp J, Siersema PD et al (2011) Long-term expansion of epithelial organoids from human colon adenoma adenocarcinoma and Barrett’s epithelium. Gastroenterology 141:1762–1772
pubmed: 21889923
doi: 10.1053/j.gastro.2011.07.050
Schepers AG, Snippert HJ, Stange DE, Van Den Born M, Van Es JH, Van De Wetering M, Clevers H (2012) Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science 337:730–735
pubmed: 22855427
doi: 10.1126/science.1224676
Shimokawa M, Ohta Y, Nishikori S, Matano M, Takano A, Fujii M, Date S, Sugimoto S, Kanai T, Sato T (2017) Visualization and targeting of LGR5 + human colon cancer stem cells. Nature 545:187–192
pubmed: 28355176
doi: 10.1038/nature22081
Siegler EL, Zhu Y, Wang P, Yang L (2018) Off-the-shelf CAR-NK cells for cancer immunotherapy. Cell Stem Cell 23:160–161
pubmed: 30075127
doi: 10.1016/j.stem.2018.07.007
Slaney CY, Wang P, Darcy PK, Kershaw MH (2018) CARs versus biTEs A comparison between T cell–redirection strategies for cancer treatment. Cancer Discov 8:924–934
pubmed: 30012854
doi: 10.1158/2159-8290.CD-18-0297
Snippert HJ, Haegebarth A, Kasper M, Jaks V, van Es JH, Barker N, van de Wetering M, van den Born M, Begthel H, Vries RG et al (2010) Lgr6 marks stem cells in the hair follicle that generate all cell lineages of the skin. Science 327:1385–1389
pubmed: 20223988
doi: 10.1126/science.1184733
Snyder JC, Rochelle LK, Lyerly HK, Caron MG, Barak LS (2013) Constitutive internalization of the Leucine-rich g protein-coupled receptor-5 (LGR5) to the trans-Golgi network. J Biol Chem 288:10286–10287
pubmed: 23439653
pmcid: 3624412
doi: 10.1074/jbc.M112.447540
Snyder JC, Rochelle LK, Ray C, Pack TF, Bock CB, Lubkov V, Lyerly HK, Waggoner AS, Barak LS, Caron MG (2017) Inhibiting clathrin-mediated endocytosis of the leucine-rich G protein-coupled receptor-5 diminishes cell fitness. J Biol Chem 292:7208–7222
pubmed: 28275053
pmcid: 5409487
doi: 10.1074/jbc.M116.756635
Tanese K, Fukuma M, Yamada T, Mori T, Yoshikawa T, Watanabe W, Ishiko A, Amagai M, Nishikawa T, Sakamoto M (2008) G-protein-coupled receptor GPR49 is up-regulated in basal cell carcinoma and promotes cell proliferation and tumor formation. Am J Pathol 173:835–843
pubmed: 18688030
pmcid: 2527081
doi: 10.2353/ajpath.2008.071091
Trejo CL, Luna G, Dravis C, Spike BT, Wahl GM (2017) Lgr5 is a marker for fetal mammary stem cells but is not essential for stem cell activity or tumorigenesis. NPJ Breast Cancer 3:1–10
doi: 10.1038/s41523-017-0018-6
Urbischek M, Rannikmae H, Foets T, Ravn K, Hyvönen M, de la Roche M (2019) Organoid culture media formulated with growth factors of defined cellular activity. Sci Rep 9:1–11
doi: 10.1038/s41598-019-42604-0
Van de Wetering M, Sancho E, Verweij C, De Lau W, Oving I, Hurlstone A, Van der Horn K, Batlle E, Coudreuse D, Haramis AP et al (2002) The β-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 111:241–250
pubmed: 12408868
doi: 10.1016/S0092-8674(02)01014-0
Waldman AD, Fritz JM, Lenardo MJ (2020) A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol 20:651–668
pubmed: 32433532
pmcid: 7238960
doi: 10.1038/s41577-020-0306-5
Walsh SJ, Omarjee S, Galloway WRJD, Kwan TTL, Sore HF, Parker JS, Hyvönen M, Carroll JS, Spring DR (2019) A general approach for the site-selective modification of native proteins enabling the generation of stable and functional antibody-drug conjugates. Chem Sci 10:694–700
pubmed: 30774870
doi: 10.1039/C8SC04645J
Yamamoto Y, Sakamoto M, Fujii G, Tsuiji H, Kanetaka K, Asaka M, Hirohashi S (2003) Overexpression of orphan G-protein-coupled receptor Gpr49 in human hepatocellular carcinomas with β-catenin mutations. Hepatology 37:528–533
pubmed: 12601349
doi: 10.1053/jhep.2003.50029
Yau T, Park J, Finn RS, Cheng A, Mathurin P, Edeline J, Kudo M, Harding JJ, Merle P, Abou-alfa GK et al (2022) Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised multicentre open-label phase 3 trial. Lancet Oncol 23:77–90
pubmed: 34914889
doi: 10.1016/S1470-2045(21)00604-5
Zhong XS, Matsushita M, Plotkin J, Riviere I, Sadelain M (2010) Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI 3 kinase/AKT/Bcl-X L activation and CD8 T cell-mediated tumor eradication. Mol Ther 18:413–420
pubmed: 19773745
doi: 10.1038/mt.2009.210
Zucman-rossi J, Villanueva A, Nault J, Llovet JM (2015) Genetic landscape and biomarkers of hepatocellular carcinoma. YGAST 149:1226–1239.e4